AbbVie Inc. 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed February 20, 2024. The filing also reports unaudited fourth-quarter 2023 results. Unless noted, financial amounts below are in U.S. dollars.
Business context
AbbVie is a global biopharmaceutical company operating as one business segment. Its portfolio spans immunology, oncology, aesthetics, neuroscience and eye care. Humira remained its largest product, representing approximately 27% of 2023 net revenue, down from 37% in 2022.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Net revenue | $54.3 billion | $58.1 billion |
| Operating earnings | $12.8 billion | $18.1 billion |
| Net earnings attributable to AbbVie | $4.9 billion | $11.8 billion |
| Diluted EPS | $2.72 | $6.63 |
| Gross margin | 62% | 70% |
| Cash from operating activities | $22.8 billion | $24.9 billion |
- Revenue decreased 6.4% reported and 5.9% at constant currency. U.S. revenue fell 8.4%; international revenue rose 0.8% reported and 3.4% at constant currency.
- Cash and equivalents were $12.8 billion at year-end. Long-term debt and finance lease obligations were $59.4 billion, including $7.2 billion current. The company had a $5.0 billion revolving credit facility with no balance outstanding at year-end; it reported covenant compliance.
- Operating cash flow declined year over year, primarily due to lower operating results and higher income tax payments. Cash dividends paid were $10.5 billion; capital expenditures were $777 million.
- Fourth-quarter 2023 revenue was $14.3 billion, gross margin was $8.6 billion, net earnings attributable to AbbVie were $822 million and diluted EPS was $0.46. The provided fourth-quarter table does not give a comparable prior-year quarter.
Material changes versus 2022
- Humira revenue fell 32% globally, including 35% in the United States, following U.S. loss of exclusivity and biosimilar competition.
- Growth in newer immunology products partly offset Humira erosion: Skyrizi revenue rose 51% and Rinvoq 58% (constant-currency basis). Vraylar rose 35%, and Botox Therapeutic rose 11%.
- Imbruvica revenue declined 21%, reflecting lower U.S. demand and market share and reduced collaboration revenue. Several established eye-care and aesthetics products also declined.
- Reported earnings were affected by $4.2 billion of intangible-asset impairment charges, including $2.1 billion for Imbruvica and $1.4 billion for CoolSculpting and Liletta, plus $630 million for an R&D asset. The company also recorded $5.1 billion of expense from revaluing contingent consideration liabilities, primarily reflecting stronger estimated Skyrizi sales.
- R&D expense increased 18% to $7.7 billion. SG&A expense declined 16%, partly because 2023 included $485 million of income from a favorable litigation settlement, while 2022 included $2.5 billion of litigation reserve charges.
Outlook, management commentary and risks
- Management’s 2024 priorities include growing Skyrizi and Rinvoq, expanding newer product launches, investing in the pipeline, managing Humira biosimilar erosion, generating cash, repaying debt and supporting dividends. The filing anticipates multiple regulatory submissions and clinical-trial readouts over the following 12 months but does not provide a clear numerical 2024 revenue or earnings forecast in the supplied text.
- Imbruvica was selected for Medicare drug-price negotiation, with negotiated prices scheduled to apply beginning in 2026. Management says future product selections and broader Inflation Reduction Act provisions could pressure pricing and revenue.
- AbbVie agreed to acquire Cerevel Therapeutics for approximately $8.7 billion, subject to closing conditions. It completed the approximately $10.1 billion ImmunoGen acquisition on February 12, 2024. The company borrowed $5.0 billion under a term-loan agreement after year-end in connection with the transactions.
- Key risks include continued Humira erosion, competition and patent challenges, pricing and reimbursement pressure, R&D and regulatory uncertainty, manufacturing or supplier disruptions, product safety and liability exposure, and substantial debt. Contingent consideration liabilities totaled $19.9 billion and depend on significant estimates of future product sales and milestones.
- Legal matters include opioid-related claims against Allergan, antitrust and securities proceedings, product-liability matters and patent litigation. For certain proceedings, AbbVie said it could not estimate possible losses beyond amounts accrued; management did not expect their ultimate disposition to materially affect consolidated results or financial position.
- AbbVie reported that cybersecurity risks had not materially affected its business, strategy, results or financial condition as of year-end. The financial statements received an unqualified audit opinion, and the auditor reported effective internal control over financial reporting.
Most important facts for investors to verify
- How quickly Skyrizi, Rinvoq and other growth products can offset Humira’s continuing biosimilar-driven declines.
- The final Medicare negotiated price for Imbruvica and the resulting commercial and impairment effects.
- Integration, financing and pipeline outcomes for the ImmunoGen acquisition and proposed Cerevel acquisition.
- The assumptions underlying the $19.9 billion contingent consideration liability and the recoverability of $55.6 billion of net intangible assets.
- Developments and potential financial exposure from material litigation, tax uncertainties and upcoming debt maturities.